title: Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium.
abstract: OBJECTIVE
  The effectiveness of instillation of mitomycin C eyedrops on the recurrence rate of pterygium was assessed in patients undergoing primary pterygium surgery. Any side effects were also noted.
  
  
  METHODS
  Primary pterygia in 38 consecutive patients were surgically excised during July to December 1992. After surgery, mitomycin C 0.02% eyedrops twice daily for 5 days as well as dexamethasone 0.1% four times tapered for the next 6 weeks were instilled. Postoperative follow up ranged from 6 to 11 months.
  
  
  RESULTS
  In one patient the pterygium recurred after 3 months (recurrence rate 2.6%). The side effects encountered were: avascularised sclera in 13 cases between 1-10 months postoperatively; ocular discomfort and lacrimation in five cases; superficial punctate keratitis during the first month in three cases; pyogenic granuloma in two cases. In one patient steroid induced increased intraocular pressure was found 4 weeks after surgery. The adverse side effects were all mild, self limiting, and easily treated.
  
  
  CONCLUSIONS
  This study suggests that postoperative instillation of mitomycin C 0.02% eyedrops twice daily for 5 days following excision of primary pterygium is an effective and safe treatment to obviate pterygium recurrence.
authors.affiliation: Department of Ophthalmology, Kaplan Hospital, Rehovot, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Rachmiel
authors.forename: H
authors.initials: H
authors.lastname: Leiba
authors.forename: S
authors.initials: S
authors.lastname: Levartovsky
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D011379:Prognosis; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control / Q000601:surgery*; D012008:Recurrence
chemical_list: D009883:Ophthalmic Solutions; D016685:Mitomycin; D003907:Dexamethasone